« And There Will Be [R&D] Blood? | Main | "Real Drugs or Sears Drugs" in EU »

02/16/2010

Pharma Biz and Clinical Updates

Facet Biotech and Bristol-Meyers Squibb report good results for Phase I/II study with their multiple myeloma drug elotuzumab as reported on MSN.

AstraZeneca (AZ) and Rigel Pharmaceuticals strike $1.24 billion pact for the Phase II rheumatoid arthritis drug fostamatinib (aka R788).  See FierceBiotech for full story.

Also reported on FierceBiotech, Thallion Pharmaceuticals and LFB Technologies sign $130 M licensing deal for treatment of Shiga-toxin producing E. coli.


Posted by Bruce Lehr Feb 16, 2010

Posted at 03:07 PM in Clinical Results, Mergers & Acquisitions, Oncology, Product Licensing/Acquisition |

| | | Pin It!

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b012877aabf42970c

Listed below are links to weblogs that reference Pharma Biz and Clinical Updates:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

The comments to this entry are closed.

Bruce Lehr

Create Your Badge
Subscribe to this blog's feed

Recent Posts

Search

Blog powered by TypePad
Member since 12/2009

Twitter Updates

    follow me on Twitter
    Bookmark and Share
    My Photo

    About

    Archives

    More...

    Categories

    May 2013

    Sun Mon Tue Wed Thu Fri Sat
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30 31  

    visited 45 states (90%)
    Create your own visited map of The United States

    Innovate on Purpose

    In the Pipeline

    Life Sci VC

    PharmaGossip

    Pharmalot

    The IN VIVO Blog


    visited 6 states (46.1%)
    Create your own visited map of Canada

    visited 8 states (3.55%)
    Create your own visited map of The World or another interesting project